Is There a Role for Levo-Thyroxine for the Treatment of Arterial Erectile Dysfunction? The Clinical Relevance of the Mean Platelet Volume.
erectile dysfunction
levo-thyroxine
mean platelet value
mean platelet volume (MPV).
peak systolic velocity
subclinical hypothyroidism
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
10 Mar 2020
10 Mar 2020
Historique:
received:
19
02
2020
revised:
06
03
2020
accepted:
09
03
2020
entrez:
14
3
2020
pubmed:
14
3
2020
medline:
14
3
2020
Statut:
epublish
Résumé
Arterial erectile dysfunction (ED) is an early sign of vascular damage. Rare evidence has been published so far as to whether subclinical hypothyroidism (SCH) affects arterial erectile function. Therefore, the objective of this study was to fill this gap. Patients with arterial ED and SCH were consecutive enrolled and randomly divided into Group A ( Group A and B did not differ for age (61.2 ± 4.8 vs. 60.3 ± 5.6 years), body-mass index (28.7 ± 2.5 vs. 28.3 ± 2.6 Kg/m Lt4 therapy is associated with an improvement of the erectile function at the vascular level, a decrease in MPV and total cholesterol. LT4 therapy should be considered in patients with arterial ED and SCH.
Sections du résumé
BACKGROUND
BACKGROUND
Arterial erectile dysfunction (ED) is an early sign of vascular damage. Rare evidence has been published so far as to whether subclinical hypothyroidism (SCH) affects arterial erectile function. Therefore, the objective of this study was to fill this gap.
METHODS
METHODS
Patients with arterial ED and SCH were consecutive enrolled and randomly divided into Group A (
RESULTS
RESULTS
Group A and B did not differ for age (61.2 ± 4.8 vs. 60.3 ± 5.6 years), body-mass index (28.7 ± 2.5 vs. 28.3 ± 2.6 Kg/m
CONCLUSIONS
CONCLUSIONS
Lt4 therapy is associated with an improvement of the erectile function at the vascular level, a decrease in MPV and total cholesterol. LT4 therapy should be considered in patients with arterial ED and SCH.
Identifiants
pubmed: 32164208
pii: jcm9030742
doi: 10.3390/jcm9030742
pmc: PMC7141360
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Andrology. 2014 Sep;2(5):709-15
pubmed: 25070238
J Sex Med. 2010 Apr;7(4 Pt 1):1381-90
pubmed: 20141582
Thyroid. 2013 Jan;23(1):31-7
pubmed: 22966899
Aging Male. 2013 Jun;16(2):29-32
pubmed: 23597264
J Clin Endocrinol Metab. 2003 Aug;88(8):3731-7
pubmed: 12915662
Niger J Physiol Sci. 2006 Jun-Dec;21(1-2):83-9
pubmed: 17242734
BJU Int. 2019 Jul 2;:
pubmed: 31267639
Int J Impot Res. 1999 Jun;11(3):141-3
pubmed: 10404282
J Clin Endocrinol Metab. 2007 May;92(5):1715-23
pubmed: 17299073
Platelets. 2011;22(2):143-7
pubmed: 21265598
Asian J Androl. 2014 May-Jun;16(3):461-6
pubmed: 24556747
Andrologia. 2019 Jun;51(5):e13248
pubmed: 30740770
Eur Urol. 2014 May;65(5):968-78
pubmed: 24011423
Thromb Haemost. 2015 Nov 25;114(6):1299-309
pubmed: 26245769
Thyroid. 2014 Dec;24(12):1670-751
pubmed: 25266247
Am J Cardiol. 2005 Dec 26;96(12B):19M-23M
pubmed: 16387561
Br J Pharmacol. 2017 Nov;174(22):3973-3985
pubmed: 28369752
Sex Med Rev. 2020 Apr;8(2):217-230
pubmed: 30458985
J Sex Med. 2019 Jul;16(7):1078-1091
pubmed: 31147249
Int J Urol. 2006 Jan;13(1):58-63
pubmed: 16448433
Pak J Med Sci. 2018 May-Jun;34(3):621-625
pubmed: 30034427
Clin Appl Thromb Hemost. 2018 Oct;24(7):1014-1019
pubmed: 29742907
Hematology. 2009 Apr;14(2):115-7
pubmed: 19298725
J Clin Endocrinol Metab. 2008 May;93(5):1815-9
pubmed: 18270255
Ann Transl Med. 2019 Jul;7(Suppl 3):S124
pubmed: 31576331
Endocr Metab Immune Disord Drug Targets. 2019;19(6):859-865
pubmed: 30727930
Ann Clin Lab Sci. 2017 Jan;47(1):29-35
pubmed: 28249913